Mithra announced plans to support the clinical development of its CSF-1R kinase inhibitor, as a monotherapy, and in combination with immune checkpoint inhibitors, following positive results in three different preclinical models.
Publication of a transparency notification received from Scorpiaux BV
Mithra Appoints Experienced Life Sciences Executive Christian Homsy as Chairman
Mithra’s General Meeting Of Shareholders Approves the Renewal of its Board of Directors
Payment of the interests of the Highbridge/Whitebox loans – Information on the total number of voting rights (denominator)
Mithra announces completion of recruitment in pediatric study of Estelle in adolescent patients
Mithra and the University of Liège Secure Proof-of-Concept for Novel Manufacturing Process of E4
Publication of a transparency notification received from Alychlo NV
Mithra Releases Invitation to its General Shareholders’ Meeting
Mithra releases 2022 Annual Report